Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
bluebird bio, Inc. (BLUE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/27/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
4
| Obenshain Andrew (President and CEO) has filed a Form 4 on bluebird bio, Inc.|
Txns:
| Sold 16,929 shares
@ $3.5416, valued at
$60k
|
|
| 08/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/08/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/06/2023 |
4
| Klima Thomas J (See Remarks) has filed a Form 4 on bluebird bio, Inc.|
Txns:
| Sold 4,130 shares
@ $3.499, valued at
$14.5k
|
|
| 05/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/05/2023 |
3
| Paulson Richard A. (Director) has filed a Form 3 on bluebird bio, Inc. |
| 04/05/2023 |
4
| Paulson Richard A. (Director) has filed a Form 4 on bluebird bio, Inc.|
Txns:
| Granted 4,663 shares
@ $0
Granted 7,500 options to buy
@ $3.3, valued at
$24.8k
|
|
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 11% stake in AMENDED FILING BLUEBIRD BIO INC |
| 03/09/2023 |
4
| Leiderman Elisabeth (Director) has filed a Form 4 on bluebird bio, Inc.|
Txns:
| Sold 1,004 shares
@ $6.4643, valued at
$6.5k
|
|
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 5.6% stake in bluebird bio, Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
SC 13G/A
| FIRST TRUST PORTFOLIOS LP reports a 0% stake in bluebird bio, Inc. |
| 01/25/2023 |
SC 13G/A
| BlackRock Inc. reports a 8.9% stake in BLUEBIRD BIO INC |
| 01/19/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
|
|
|